Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that significantly increases survival for patients with previously treated advanced non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors have been reported to be particularly effective in Asian patients and may have a distinct safety profile in this population compared with non-Asian patients. We report safety and efficacy data from a subpopulation of East/South-East (E/SE) Asian patients enrolled in a global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment study).
著者Mok T, Wu YL, Au JSK, Zhou CC, Zhang L, Perng RP, Park K
期刊名稱Journal of Thoracic Oncology
出版年份2010
月份10
日期1
卷號5
期次10
出版社Lippincott, Williams & Wilkins
頁次1609 - 1615
國際標準期刊號1556-0864
電子國際標準期刊號1556-1380
語言英式英語
關鍵詞Asia; Erlotinib; NSCLC; Phase IV; TRUST
Web of Science 學科類別Oncology; ONCOLOGY; Respiratory System; RESPIRATORY SYSTEM

上次更新時間 2020-17-10 於 23:55